DHRS11

Summary

DHRS11 (dehydrogenase/reductase 11, HGNC:28639) is a protein-coding gene on chromosome 17q12, encoding Dehydrogenase/reductase SDR family member 11 (Q6UWP2). Catalyzes the conversion of the 17-keto group of estrone, 4- and 5-androstenes and 5-alpha-androstanes into their 17-beta-hydroxyl metabolites and the conversion of the 3-keto group of 3-, 3,17- and 3,20- diketosteroids into their 3beta-hydroxyl metabolites.

Enables 17-beta-hydroxysteroid dehydrogenase (NADP+) activity; 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity; and estradiol 17-beta-dehydrogenase [NAD(P)+] activity. Involved in steroid biosynthetic process. Predicted to be located in extracellular region.

Source: NCBI Gene 79154 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 52 total — 2 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_024308

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28639
Approved symbol	DHRS11
Name	dehydrogenase/reductase 11
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	MGC4172, SDR24C1
Ensembl gene	ENSG00000278535
Ensembl biotype	protein_coding
OMIM	616159
Entrez	79154

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 16 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000610443, ENST00000611337, ENST00000612205, ENST00000612538, ENST00000615432, ENST00000617959, ENST00000618403, ENST00000621871, ENST00000852272, ENST00000852273, ENST00000852274, ENST00000852275, ENST00000852276, ENST00000852277, ENST00000852278, ENST00000852279, ENST00000940549, ENST00000940550, ENST00000951342, ENST00000951343

RefSeq mRNA: 1 — MANE Select: NM_024308 NM_024308

CCDS: CCDS11315

Canonical transcript exons

ENST00000618403 — 7 exons

Exon	Start	End
ENSE00003717924	36598163	36598257
ENSE00003725716	36599972	36600037
ENSE00003744600	36600162	36600804
ENSE00003747785	36599671	36599763
ENSE00003748814	36598921	36599050
ENSE00003749575	36594971	36595180
ENSE00003754415	36591879	36592156

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.8854 / max 517.6657, expressed in 1635 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160437	9.8228	1633
160438	0.0626	19

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	99.17	gold quality
mucosa of transverse colon	UBERON:0004991	98.96	gold quality
rectum	UBERON:0001052	97.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.28	gold quality
transverse colon	UBERON:0001157	94.09	gold quality
small intestine	UBERON:0002108	94.06	gold quality
primary visual cortex	UBERON:0002436	91.65	gold quality
superior frontal gyrus	UBERON:0002661	91.05	gold quality
right frontal lobe	UBERON:0002810	90.40	gold quality
intestine	UBERON:0000160	90.14	gold quality
frontal cortex	UBERON:0001870	90.00	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	89.91	gold quality
apex of heart	UBERON:0002098	89.83	gold quality
prefrontal cortex	UBERON:0000451	89.81	gold quality
anterior cingulate cortex	UBERON:0009835	89.74	gold quality
lower esophagus mucosa	UBERON:0035834	89.46	gold quality
putamen	UBERON:0001874	89.29	gold quality
cerebral cortex	UBERON:0000956	89.24	gold quality
Brodmann (1909) area 9	UBERON:0013540	89.10	gold quality
colon	UBERON:0001155	88.69	gold quality
hypothalamus	UBERON:0001898	88.33	gold quality
caudate nucleus	UBERON:0001873	87.89	gold quality
nucleus accumbens	UBERON:0001882	87.77	gold quality
brain	UBERON:0000955	87.75	gold quality
adult mammalian kidney	UBERON:0000082	87.15	gold quality
colonic epithelium	UBERON:0000397	87.14	gold quality
Ammon’s horn	UBERON:0001954	86.97	gold quality
temporal lobe	UBERON:0001871	86.94	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.94	gold quality
amygdala	UBERON:0001876	86.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting DHRS11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-3138	98.41	67.53	744
HSA-MIR-4450	98.26	68.35	725
HSA-MIR-93-3P	98.15	66.65	1309

Literature-anchored findings (GeneRIF, showing 2)

• The recombinant protein (DHRS11) efficiently catalyzed the conversion of the 17-keto group of estrone, 4- and 5-androstenes and 5alpha-androstanes into their 17beta-hydroxyl metabolites with NADPH as a coenzyme. (PMID:26920053)
• Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C19-steroids. (PMID:31926269)

Cross-species orthologs

18 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhrs11a	ENSDARG00000046090
mus_musculus	Dhrs11	ENSMUSG00000034449
rattus_norvegicus	Dhrs11	ENSRNOG00000027891
drosophila_melanogaster	Antdh	FBGN0026268
drosophila_melanogaster	CG10962	FBGN0030073
drosophila_melanogaster	CG9360	FBGN0030332
drosophila_melanogaster	CG9150	FBGN0031775
drosophila_melanogaster	CG8757	FBGN0036380
drosophila_melanogaster	CG3301	FBGN0038878
drosophila_melanogaster	CG40485	FBGN0069973
drosophila_melanogaster	CG40486	FBGN0263830
caenorhabditis_elegans		WBGENE00000970
caenorhabditis_elegans		WBGENE00000975
caenorhabditis_elegans		WBGENE00000981
caenorhabditis_elegans		WBGENE00008985
caenorhabditis_elegans		WBGENE00008986
caenorhabditis_elegans		WBGENE00011424
caenorhabditis_elegans		WBGENE00022809

Paralogs (13): RDH8 (ENSG00000080511), DHRS7 (ENSG00000100612), DHRS2 (ENSG00000100867), DHRS7B (ENSG00000109016), HSD11B1 (ENSG00000117594), HSDL2 (ENSG00000119471), DHRS4 (ENSG00000157326), DHRS1 (ENSG00000157379), CBR1 (ENSG00000159228), CBR3 (ENSG00000159231), HSD11B1L (ENSG00000167733), DHRS7C (ENSG00000184544), DHRS4L2 (ENSG00000187630)

Protein

Protein identifiers

Dehydrogenase/reductase SDR family member 11 — Q6UWP2 (reviewed: Q6UWP2)

Alternative names: 17-beta-hydroxysteroid dehydrogenase, 3-beta-hydroxysteroid 3-dehydrogenase, Estradiol 17-beta-dehydrogenase, Short-chain dehydrogenase/reductase family 24C member 1

All UniProt accessions (4): Q6UWP2, A0A087WYV4, A0A087WZN3, A0A087X0R1

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the conversion of the 17-keto group of estrone, 4- and 5-androstenes and 5-alpha-androstanes into their 17-beta-hydroxyl metabolites and the conversion of the 3-keto group of 3-, 3,17- and 3,20- diketosteroids into their 3beta-hydroxyl metabolites. Exhibits reductive 3-beta-hydroxysteroid dehydrogenase activity toward 5-beta-androstanes, 5-beta-pregnanes, 4-pregnenes and bile acids. May contribute to the metabolism of adrenal-derived androgen precursors. Reduces 11-keto-4-androstene-3,17-dione (11KA4) and 11-keto-5alpha-androstane-3,17-dione (11K-Adione) into potent androgens 11-ketotestosterone (11KT) and 11-ketodihydrotestosterone (11KDHT), respectively. May also reduce endogenous and exogenous alpha-dicarbonyl compounds and xenobiotic alicyclic ketones.

Subunit / interactions. Homotetramer.

Subcellular location. Secreted.

Tissue specificity. Isoform 1: Ubiquitously expressed, with highest levels in testis, small intestine, colon, kidney, brain and heart. Isoform 3: Expressed in brain, heart and skeletal muscle.

Activity regulation. Inhibited by flavonoids including apigenin, luteolin, genistein, kaempferol and quercetin and also by carbenoxolone, zearalenone, glycyrrhetinic, curcumin and flufenamic acid.

Pathway. Steroid biosynthesis; estrogen biosynthesis.

Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6UWP2-1	1	yes
Q6UWP2-2	2
Q6UWP2-3	3

RefSeq proteins (1): NP_077284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002347	SDR_fam	Family
IPR020904	Sc_DH/Rdtase_CS	Conserved_site
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily

Pfam: PF00106

Catalyzed reactions (Rhea), 6 shown:

• 17beta-estradiol + NADP(+) = estrone + NADPH + H(+) (RHEA:24616)
• a 3beta-hydroxysteroid + NADP(+) = a 3-oxosteroid + NADPH + H(+) (RHEA:34787)
• androst-4-ene-3,11,17-trione + NADPH + H(+) = 17beta-hydroxyandrost-4-ene-3,11-dione + NADP(+) (RHEA:53484)
• a 17beta-hydroxy steroid + NADP(+) = a 17-oxo steroid + NADPH + H(+) (RHEA:69284)
• 5alpha-androstan-3,11,17-trione + NADPH + H(+) = 17beta-hydroxy-5alpha-androstan-3,11-dione + NADP(+) (RHEA:85531)
• 3alpha-hydroxy-5alpha-androstan-11,17-dione + NADPH + H(+) = 3alpha,17beta-dihydroxy-5alpha-androstan-11-one + NADP(+) (RHEA:85543)

UniProt features (41 total): helix 12, binding site 11, strand 7, splice variant 2, mutagenesis site 2, turn 2, signal peptide 1, chain 1, site 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1XG5	X-RAY DIFFRACTION	1.53

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UWP2-F1	97.78	0.99

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 200 (important for the strict 17beta-hydroxysteroid dehydrogenase activity); 166 (proton acceptor)

Ligand- & substrate-binding residues (11): 166; 170; 201–204; 208; 18–23; 43–44; 49; 70–71; 97; 151; 166

Mutagenesis-validated functional residues (2):

Position	Phenotype
163	decreases the reductase activity toward androstane substrates including androst-4-ene-3,11,17-trione (11ka4), 5alpha-and
200	switches the positional specificity of the reductase activity from 17beta to 3beta. acquires 3beta-hydroxysteroid dehydr

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 114 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_REGULATION_OF_HORMONE_LEVELS, TGACCTY_ERR1_Q2, MODULE_453, GGGTGGRR_PAX4_03, GOMF_STEROID_DEHYDROGENASE_ACTIVITY_ACTING_ON_THE_CH_OH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, CATRRAGC_UNKNOWN, GTGTTGA_MIR505, GOBP_HORMONE_BIOSYNTHETIC_PROCESS, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, SABATES_COLORECTAL_ADENOMA_DN, BASAKI_YBX1_TARGETS_UP

GO Biological Process (4): steroid biosynthetic process (GO:0006694), estrogen biosynthetic process (GO:0006703), lipid metabolic process (GO:0006629), steroid metabolic process (GO:0008202)

GO Molecular Function (7): nucleotide binding (GO:0000166), 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity (GO:0000253), estradiol 17-beta-dehydrogenase [NAD(P)+] activity (GO:0004303), 17-beta-hydroxysteroid dehydrogenase (NADP+) activity (GO:0072582), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616)

GO Cellular Component (1): extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3
steroid metabolic process	1
lipid biosynthetic process	1
estrogen metabolic process	1
hormone biosynthetic process	1
steroid hormone biosynthetic process	1
primary metabolic process	1
lipid metabolic process	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on CH-OH group of donors	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3481 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHRS11	HSD17B1	P14061	964
DHRS11	HSD17B2	P37059	935
DHRS11	HSD17B4	P51659	922
DHRS11	HSD17B7	P56937	897
DHRS11	HSD17B10	Q99714	884
DHRS11	HSD3B1	P14060	882
DHRS11	FSIP1	Q8NA03	881
DHRS11	CYP19A1	P11511	850
DHRS11	CYP17A1	P05093	837
DHRS11	HSD3B2	P26439	808
DHRS11	STAR	P49675	738
DHRS11	ESR1	P03372	738
DHRS11	HSD11B2	P80365	728
DHRS11	AKR1C3	P42330	727
DHRS11	CYP11A1	P05108	718

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CYREN	ACOX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): DHRS11 (Co-fractionation), HARS (Co-fractionation), NAPRT (Co-fractionation), TPI1 (Co-fractionation), TSTA3 (Co-fractionation), DHRS11 (Two-hybrid), DHRS11 (Affinity Capture-MS), DHRS11 (Affinity Capture-MS), DHRS11 (Affinity Capture-MS)

ESM2 similar proteins: A0A223HDI5, A3QK15, O00097, P00333, P00504, P04181, P04182, P07754, P08843, P0C0Y4, P0C0Y5, P12863, P14219, P14673, P14674, P14675, P25141, P28032, P29401, P29758, P33097, P34937, P37769, P40142, P41177, P41747, P46226, P48491, P48493, P48494, P48495, P49724, P50137, Q05528, Q07264, Q0II68, Q29RZ0, Q2R8Z5, Q2U919, Q3ZCF5

Diamond homologs: A0A017SEY2, A0A023I4F1, A0A0C6DRT7, A0A1B7YCL6, A0A2P1DP77, A0A345BJN5, A0A482ND39, A0A4P8DJW5, A0A5B8YU33, A0AAW1NHX6, A2RVM0, B2X050, B6H062, B6HLP6, B8M9L2, C8V3Y7, D7UQ42, F4JJR8, G1XTZ5, G3Y422, G4MVZ5, G9N4A1, G9N4A6, I1S2J3, O48741, O75828, O80333, P00335, P0DXW2, P15428, P16232, P19992, P21218, P28845, P42317, P50199, P50203, P51975, P70684, P9WEF8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	40
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2580315	GRCh37/hg19 17q12(chr17:34752221-36105007)x3	Pathogenic
997073	GRCh37/hg19 17q12(chr17:34437475-36243028)	Pathogenic

SpliceAI

1575 predictions. Top by Δscore:

Variant	Effect	Δscore
17:36592156:GGT:G	donor_loss	1.0000
17:36592157:GTG:G	donor_loss	1.0000
17:36595181:G:GG	donor_gain	1.0000
17:36598158:TGCAG:T	acceptor_loss	1.0000
17:36598160:CAGG:C	acceptor_loss	1.0000
17:36598254:A:AG	donor_gain	1.0000
17:36598254:ATAG:A	donor_loss	1.0000
17:36598258:G:GA	donor_loss	1.0000
17:36598919:A:AG	acceptor_gain	1.0000
17:36598919:AGCAT:A	acceptor_gain	1.0000
17:36598920:G:GA	acceptor_gain	1.0000
17:36598920:GC:G	acceptor_gain	1.0000
17:36598920:GCAT:G	acceptor_gain	1.0000
17:36598920:GCATG:G	acceptor_gain	1.0000
17:36599049:CGGT:C	donor_loss	1.0000
17:36599050:GGTGA:G	donor_loss	1.0000
17:36599051:G:GG	donor_gain	1.0000
17:36599051:GT:G	donor_loss	1.0000
17:36599820:G:GT	donor_gain	1.0000
17:36599820:G:T	donor_gain	1.0000
17:36599960:T:TA	acceptor_gain	1.0000
17:36599970:A:AG	acceptor_gain	1.0000
17:36599971:G:GG	acceptor_gain	1.0000
17:36599971:GT:G	acceptor_gain	1.0000
17:36595162:TTGG:T	donor_gain	0.9900
17:36595179:AT:A	donor_gain	0.9900
17:36595181:G:A	donor_loss	0.9900
17:36598153:T:TA	acceptor_gain	0.9900
17:36598154:G:A	acceptor_gain	0.9900
17:36598161:A:AG	acceptor_gain	0.9900

AlphaMissense

1691 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:36599677:T:C	S197P	0.997
17:36592062:G:A	G18E	0.996
17:36592080:G:A	G24D	0.996
17:36595111:C:A	N96K	0.996
17:36595111:C:G	N96K	0.996
17:36595163:T:A	W114R	0.996
17:36595163:T:C	W114R	0.996
17:36598181:A:C	S126R	0.996
17:36598183:C:A	S126R	0.996
17:36598183:C:G	S126R	0.996
17:36598194:G:C	R130P	0.996
17:36592061:G:T	G18W	0.995
17:36598929:G:A	G154D	0.995
17:36598971:C:A	A168D	0.995
17:36598978:G:C	K170N	0.995
17:36598978:G:T	K170N	0.995
17:36599019:T:C	L184P	0.995
17:36592128:G:A	G40D	0.994
17:36598168:C:A	N121K	0.994
17:36598168:C:G	N121K	0.994
17:36598187:T:C	C128R	0.994
17:36599675:T:A	I196N	0.994
17:36599696:C:T	T203I	0.994
17:36598199:G:C	A132P	0.993
17:36598974:C:T	T169I	0.993
17:36598977:A:C	K170T	0.993
17:36598977:A:T	K170M	0.993
17:36598983:C:A	A172D	0.993
17:36598995:T:C	L176P	0.993
17:36599007:T:C	L180P	0.993

dbSNP variants (sampled 300 via entrez): RS1000369345 (17:36594414 C>G,T), RS1000396745 (17:36594744 A>G), RS1000546280 (17:36590670 A>G), RS1000970103 (17:36593110 G>A), RS1001525507 (17:36593091 C>T), RS1001758585 (17:36599745 C>A,T), RS1001917231 (17:36598553 T>C,G), RS1001974175 (17:36592080 G>A), RS1002210857 (17:36599450 C>G,T), RS1002977432 (17:36590607 T>C), RS1003107862 (17:36596515 C>A,G,T), RS1003407692 (17:36590931 A>G), RS1003499980 (17:36597148 T>A,C), RS1003643541 (17:36593450 A>G), RS1003719555 (17:36596874 A>G)

Disease associations

OMIM: gene MIM:616159 | disease phenotypes: MIM:616025, MIM:614527

GenCC curated gene-disease

Mondo (3): hyperphosphatasia with intellectual disability syndrome 5 (MONDO:0014457), chromosome 17q12 deletion syndrome (MONDO:0013797), polyhydramnios (MONDO:0004585)

Orphanet (2): Hyperphosphatasia-intellectual disability syndrome (Orphanet:247262), 17q12 microdeletion syndrome (Orphanet:261265)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001561	Polyhydramnios

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005951_15	Body mass index	3.000000e-13
GCST007876_78	Estimated glomerular filtration rate	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006831	Polyhydramnios	C12.050.703.610

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

86 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
mercuric bromide	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	decreases methylation, increases expression	2
Cyclosporine	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
9,10-phenanthrenequinone	increases reduction	1
pirinixic acid	affects binding, increases activity, increases expression	1
kaempferol	decreases activity	1
androstane-3,17-dione	increases reduction	1
bisphenol A	decreases expression	1
sodium arsenate	increases abundance, decreases expression	1
quercitrin	decreases activity	1
tris(2-butoxyethyl) phosphate	affects expression	1
beta-lapachone	decreases expression	1
arsenite	decreases expression, increases abundance	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
estrone sulfate	increases reduction	1
monomethylarsonic acid	decreases expression	1
zomepirac	decreases activity	1
zinc chromate	increases abundance, decreases expression	1
acenaphthenequinone	increases reduction	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
arsenic acid	decreases expression, increases abundance	1

Clinical trials (associated diseases)

7 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01238250	Not specified	RECRUITING	Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
NCT00236340	Not specified	COMPLETED	Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.
NCT03277417	Not specified	UNKNOWN	Does Amniotic Fluid Index Affect the Fetal Cardiac Performance?
NCT04497532	Not specified	UNKNOWN	Influence of Diet on Pregnancy With Polyhydramnios
NCT05043753	Not specified	RECRUITING	Fetal gRowth AbnorMality dEtection Trial
NCT05059093	Not specified	COMPLETED	Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
NCT07067593	Not specified	NOT_YET_RECRUITING	Amnioreduction in Polyhydramnios